Agios Pharmaceuticals: A More Compelling Valuation
…
28,500€
Echtzeit-Aktienkurs Agios Pharmaceuticals
Bid:
Ask:
Nachrichten zur Agios Pharmaceuticals Aktie
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism…
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
…
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -0.58% and 11.76%, respectively, for the quarter ended December 2024. Do…
Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision
…
Agios Pharmaceuticals: A Long Overdue Follow Up
…
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism…
Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
…
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain…
Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?
The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this…
Agios Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
…
Agios Pharmaceuticals, Inc. (AGIO) Q1 2024 Earnings Call Transcript
…